Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease

Abstract Background Several studies have shown that patients with anti-MDA5 antibody-positive dermatomyositis (anti-MDA5 antibody + DM) have an increased risk of developing rapid progression of interstitial lung disease (RPILD), which is associated with poor prognosis and high mortality. However, di...

Full description

Bibliographic Details
Published in:	Arthritis Research & Therapy
Main Authors:	Kaikai Zhao, Juan Zhang, Qunyu Kong, Yong Zhang, Cong Li, Kaikai Huo, Na Fan, Wenjing Deng, Jie Shi, Chunya Wang, Xueyi Li, Shuanying Yang, Ping Fang
Format:	Article
Language:	English
Published:	BMC 2025-02-01
Subjects:	Anti-MDA5 antibody Dermatomyositis Interstitial lung disease Prognostic factors
Online Access:	https://doi.org/10.1186/s13075-025-03485-z

Similar Items

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
by: Houari Aissaoui, et al.
Published: (2021-04-01)

Pneumomediastinum and Pneumopericardium in Rapidly Progressive Interstitial Lung Disease Secondary to Anti‐MDA5 Dermatomyositis
by: Thomas Bond, et al.
Published: (2025-10-01)

Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis
by: Yulu Qiu, et al.
Published: (2024-01-01)

Amyopathic dermatomyositis with a rapidly progressing interstitial pneumonia
by: Darija Logvinova, et al.
Published: (2024-11-01)

Clinical and Molecular Insights Into Anti-MDA5 Antibody-Positive Dermatomyositis: A Single-Center Retrospective and Transcriptomic Study
by: Ren Y, et al.
Published: (2025-08-01)

Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study
by: Hongxia Xin, et al.
Published: (2025-01-01)

Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort
by: Sai K. Koyoda, et al.
Published: (2025-01-01)

Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering
by: Ruru Guo, et al.
Published: (2024-03-01)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
by: Zong Jiang, et al.
Published: (2023-06-01)

Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective study
by: Tulaton Sodsri, et al.
Published: (2025-08-01)

Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study
by: Qiang Ji, et al.
Published: (2023-11-01)

Anti-MDA5 antibody-positive dermatomyositis with severe cutaneous ulcers
by: Büşra Demirbağ Gül, et al.
Published: (2022-12-01)

Anti-MDA-5 dermatomyositis with tumid lupus-like lesions
by: Kristiana Marie Jordan, BA, et al.
Published: (2025-06-01)

Lung infection or inflammation-a puzzling case of MDA-5 associated juvenile dermatomyositis
by: Anusha Vuppala, et al.
Published: (2023-12-01)

Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease
by: Wang CR, et al.
Published: (2023-12-01)

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
by: Huyan Wang, et al.
Published: (2023-07-01)

Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system
by: Jiajia Jin, et al.
Published: (2025-10-01)

Anti-MDA5 Positive Dermatomyositis Overlapping with Rheumatoid Arthritis: A Case Report
by: Yuan F, et al.
Published: (2025-09-01)

Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study
by: Xu X, et al.
Published: (2025-02-01)

Clinical features and prognostic factors of anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients
by: Li Lian, et al.
Published: (2023-06-01)

Panniculitis in Anti-MDA-5 Positive Juvenile Dermatomyositis: A Case Report
by: Semra Ayduran, et al.
Published: (2024-12-01)

Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib
by: Valentina Natoli, et al.
Published: (2025-02-01)

Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease
by: Yuanyuan Niu, et al.
Published: (2024-10-01)

Low Circulating Monocytes Is in Parallel With Lymphopenia Which Predicts Poor Outcome in Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Associated Interstitial Lung Disease
by: Xia Lv, et al.
Published: (2022-01-01)

Identifying two pathways to poor prognosis in patients with anti-MDA5 antibodies: insights from prognostic factor and cytokines analysis
by: Aya Shimizu, et al.
Published: (2025-04-01)

Anti-MDA5 Amyopathic Dermatomyositis—A Diagnostic and Therapeutic Challenge
by: Anca Bobirca, et al.
Published: (2022-07-01)

Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease
by: Fang-Ping Ren, et al.
Published: (2023-10-01)

Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review
by: Lingzhi Qiu, et al.
Published: (2024-11-01)

Dysregulated type I/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis
by: Akira Yoshida, et al.
Published: (2025-07-01)

Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case–Control Study
by: Chenghua Weng, et al.
Published: (2023-02-01)

Machine learning for screening and predicting the risk of anti-MDA5 antibody in juvenile dermatomyositis children
by: Yuan Xue, et al.
Published: (2023-01-01)

A Review of MDA-5 Dermatomyositis and Associated Interstitial Lung Disease
by: Sambhawana Bhandari, et al.
Published: (2024-02-01)

Multisystemic Complications and Rapid Decline in Anti‐MDA‐5 Positive Amyopathic Dermatomyositis: A Case Study
by: Hem Prajapati, et al.
Published: (2025-03-01)

Coexistence of anti‐MDA5 and anti‐PL‐7 in a patient with dermatomyositis: A case report
by: Hongyan Fu, et al.
Published: (2023-01-01)

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis
by: Tao Liu, et al.
Published: (2022-08-01)

Infection Risk in Patients with Dermatomyositis Associated with Anti-MDA5 Antibodies: A Historical Cohort Study
by: Anne-Claire Billet, et al.
Published: (2022-12-01)

Uncommon concurrent pulmonary infections: Aspergillus fumigatus and Lomentospora prolificans in an Anti-MDA5 antibody-positive dermatomyositis patient
by: Maaya Fukumura, et al.
Published: (2025-03-01)

Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis
by: Yixue Guo, et al.
Published: (2024-11-01)

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients
by: Jinjing Qian, et al.
Published: (2023-03-01)

A less common case of anti‐MDA5 and anti‐Ro52 antibody‐positive juvenile dermatomyositis complicated with macrophage activation syndrome
by: Li Zhang, et al.
Published: (2024-03-01)